Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
7.59
-0.31 (-3.92%)
At close: Feb 21, 2025, 4:00 PM
7.85
+0.26 (3.43%)
After-hours: Feb 21, 2025, 6:05 PM EST
Contineum Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Contineum Therapeutics stock have an average target of 29.25, with a low estimate of 25 and a high estimate of 32. The average target predicts an increase of 285.38% from the current stock price of 7.59.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2025.
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +308.43% | Jan 9, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $32 → $31 | Buy | Maintains | $32 → $31 | +308.43% | Nov 7, 2024 |
| Baird | Baird | Buy Initiates $32 | Buy | Initiates | $32 | +321.61% | Oct 22, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $30 → $32 | Buy | Maintains | $30 → $32 | +321.61% | Aug 14, 2024 |
| Stifel | Stifel | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +282.08% | Apr 30, 2024 |
Financial Forecast
Revenue This Year
n/a
from 50.00M
Revenue Next Year
6.12M
EPS This Year
-1.95
from 0.08
EPS Next Year
-1.84
from -1.95
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | n/a | 31.5M | 52.5M |
| Avg | n/a | 6.1M | 12.8M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 757.8% |
| Avg | - | - | 108.3% |
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.59 | -0.75 | -2.54 |
| Avg | -1.95 | -1.84 | -3.17 |
| Low | -2.07 | -2.50 | -3.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.